Reviewing Evogene (EVGN) and The Competition

Evogene (NASDAQ: EVGN) is one of 22 publicly-traded companies in the “Agricultural chemicals” industry, but how does it contrast to its competitors? We will compare Evogene to related businesses based on the strength of its valuation, dividends, analyst recommendations, institutional ownership, profitability, earnings and risk.


This table compares Evogene and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Evogene -616.33% -27.15% -24.51%
Evogene Competitors -1,647.77% -12.02% -10.38%

Analyst Ratings

This is a summary of current ratings and recommmendations for Evogene and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evogene 0 0 0 0 N/A
Evogene Competitors 173 578 648 38 2.38

As a group, “Agricultural chemicals” companies have a potential upside of 13.23%. Given Evogene’s competitors higher possible upside, analysts plainly believe Evogene has less favorable growth aspects than its competitors.

Risk & Volatility

Evogene has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, Evogene’s competitors have a beta of 0.53, meaning that their average stock price is 48% less volatile than the S&P 500.

Insider & Institutional Ownership

35.5% of Evogene shares are owned by institutional investors. Comparatively, 37.4% of shares of all “Agricultural chemicals” companies are owned by institutional investors. 13.7% of shares of all “Agricultural chemicals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Evogene and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Evogene $3.38 million -$20.83 million -3.79
Evogene Competitors $3.12 billion $272.01 million 0.31

Evogene’s competitors have higher revenue and earnings than Evogene. Evogene is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


Evogene competitors beat Evogene on 8 of the 10 factors compared.

About Evogene

Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd. (Evofuel). It operates through two segments. Its Evogene segment develops seed traits, ag-chemical products, and ag-biological products to improve plant performance. The Company’s Evofuel segment develops species of the castor bean plant for second generation feedstock for biofuel and other industrial uses. Its Crop Enhancement (CE) division is developing two types of products: CE seed traits, are seed traits having improved yield and abiotic stress tolerance, and ag-biologicals, which focuses on microbial-based bio-stimulants. The Company’s Crop Protection (CP) division is developing two types of products: CP seed traits and ag-chemicals.

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with's FREE daily email newsletter.

Leave a Reply